title: G-CSF for imatinib-induced neutropenia.
authors.forename: D
authors.initials: D
authors.lastname: Heim
authors.forename: M
authors.initials: M
authors.lastname: Ebnöther
authors.forename: S
authors.initials: S
authors.lastname: Meyer-Monard
authors.forename: D
authors.initials: D
authors.lastname: Tsakiris
authors.forename: M
authors.initials: M
authors.lastname: Linn
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000097:blood / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy; D015465:Leukemia, Myeloid, Accelerated Phase / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate